CPhI Online

- Biopharma News

Samsung Biologics to provide fill-finish manufacturing for Moderna COVID vaccine

24 May 2021

The CDMO will support the production of hundreds of millions of doses from its facility in Incheon, South Korea.

Samsung Biologics has signed a manufacturing services and supply agreement with Moderna in which the CDMO will provide large-scale, commercial fill-finish manufacturing for the biotech's COVID-19 vaccine, mRNA-1273.

Upon execution of the deal, tech transfer will start immediately and Samsung Biologics will perform aseptic fill-finish, labeling, and packaging services from its Incheon, South Korea site, to support the production of hundreds of millions of doses of Moderna’s COVID-19 vaccine, intended for the supply of markets outside of the US starting in the third quarter of 2021.

John Rim, CEO of Samsung Biologics, said that the company has "set immediate action plans and schedule to make mRNA-1273 available for commercial distribution in the early second half of 2021" in response to the immediate urgency of supplying the vaccine worldwide.

According to its Q1 2021 financial results report, Samsung Biologics says its existing plants are at near full operation. The construction of its Plant 4 or 'Super Plant' — what has been hailed as the world's largest biomanufacturing facility — also in Incheon, remains on track.

Read More

Related Content